全文获取类型
收费全文 | 154813篇 |
免费 | 32838篇 |
国内免费 | 2416篇 |
专业分类
耳鼻咽喉 | 5212篇 |
儿科学 | 5612篇 |
妇产科学 | 2556篇 |
基础医学 | 4090篇 |
口腔科学 | 1677篇 |
临床医学 | 27112篇 |
内科学 | 48347篇 |
皮肤病学 | 7529篇 |
神经病学 | 15386篇 |
特种医学 | 6414篇 |
外科学 | 41198篇 |
综合类 | 266篇 |
现状与发展 | 72篇 |
一般理论 | 9篇 |
预防医学 | 7636篇 |
眼科学 | 3440篇 |
药学 | 1372篇 |
中国医学 | 23篇 |
肿瘤学 | 12116篇 |
出版年
2024年 | 692篇 |
2023年 | 4859篇 |
2022年 | 1336篇 |
2021年 | 3341篇 |
2020年 | 6153篇 |
2019年 | 2382篇 |
2018年 | 7609篇 |
2017年 | 7465篇 |
2016年 | 8572篇 |
2015年 | 8617篇 |
2014年 | 15694篇 |
2013年 | 15890篇 |
2012年 | 5948篇 |
2011年 | 5905篇 |
2010年 | 10582篇 |
2009年 | 14398篇 |
2008年 | 6131篇 |
2007年 | 4261篇 |
2006年 | 6767篇 |
2005年 | 4024篇 |
2004年 | 3229篇 |
2003年 | 2198篇 |
2002年 | 2214篇 |
2001年 | 3833篇 |
2000年 | 3029篇 |
1999年 | 3234篇 |
1998年 | 3669篇 |
1997年 | 3475篇 |
1996年 | 3381篇 |
1995年 | 3229篇 |
1994年 | 1951篇 |
1993年 | 1575篇 |
1992年 | 1393篇 |
1991年 | 1428篇 |
1990年 | 1073篇 |
1989年 | 1192篇 |
1988年 | 1040篇 |
1987年 | 868篇 |
1986年 | 896篇 |
1985年 | 730篇 |
1984年 | 565篇 |
1983年 | 539篇 |
1982年 | 530篇 |
1981年 | 411篇 |
1980年 | 372篇 |
1979年 | 316篇 |
1978年 | 339篇 |
1977年 | 404篇 |
1975年 | 286篇 |
1972年 | 308篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献43.
44.
45.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
46.
47.
48.
49.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
50.
Marie V. Plaisime PhD MPH Marie Jipguep-Akhtar PhD Joseph J. Locascio PhD Harolyn M. E. Belcher MD MHS Rachel R. Hardeman PhD MPH Katherine Picho-Kiroga PhD Sylvia P. Perry PhD Sean M. Phelan PhD MPH Michelle van Ryn PhD LMFT MPH John F. Dovidio PhD 《Health services research》2023,58(Z2):229-237